<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605891</url>
  </required_header>
  <id_info>
    <org_study_id>US/PR/033009/001/05</org_study_id>
    <secondary_id>EudraCT Number: 2006-000531-10</secondary_id>
    <nct_id>NCT00605891</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of CHF 4226 for Treating Patients With COPD</brief_title>
  <official_title>A Randomized, Controlled,14-Treatment Day, Multicenter Study to Determine the Optimal Efficacious and Safe Dose of CHF 4226 in a Metered Dose Inhaler in Treating Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be
      further developed for the treatment of patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Day 1 to Day 14 (+3 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>10 and 30 min, 1, 2, and 3 hrs post dose on Day 1, Day 2 and Day 14 (+3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG/QTc</measure>
    <time_frame>pre dose and post dose at 30' on Days 1, 2 and 14 (+3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum potassium</measure>
    <time_frame>pre dose and post dose at 30' on Days 1, 2 and 14 (+3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>pre dose and post dose at 30' on Days 1, 2 and 14 (+3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>10 and 30 min, 1, 2, and 3 hrs post dose on Day 1, Day 2 and Day 14 (+3)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carmoterol (CHF 4226) 1.0 μg once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carmoterol (CHF 4226) 2.0 μg once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carmoterol (CHF 4226) 4.0 μg once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol 50 μg BID, in the morning and in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmoterol (CHF 4226)</intervention_name>
    <description>carmoterol pMDI 2.0 μg once a day, in the morning
(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>CHF 4226</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmoterol (CHF 4226)</intervention_name>
    <description>carmoterol pMDI 1.0 μg once a day, in the morning
(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))</description>
    <arm_group_label>A</arm_group_label>
    <other_name>CHF 4226</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmoterol (CHF 4226)</intervention_name>
    <description>carmoterol pMDI 4.0 μg once a day, in the morning
(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)</description>
    <arm_group_label>C</arm_group_label>
    <other_name>CHF 4226</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <description>Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)</description>
    <arm_group_label>E</arm_group_label>
    <other_name>Serevent® Diskus®/Accuhaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has signed an IRB-/Ethics Committee-approved Informed Consent form

          -  Patient is a male or non-pregnant female between the ages of 40 - 75 years, inclusive

          -  Patient has a current or past smoking history of at least 15 pack-years

          -  Patient has a clinical diagnosis of COPD in accordance with the recommendations of the
             National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO) Global
             Initiative for Chronic Obstructive Lung Disease (GOLD)

          -  Patient meets the following requirements after an FEV1 albuterol reversibility test
             (i.e., 30 minutes following 200 mcg (metered dose) albuterol/salbutamol pMDI):

          -  FEV1 is at least 0.9L

          -  FEV1 of 40% - 70%, inclusive, of patient's predicted normal value

          -  Change in FEV1 &gt; 4% of patient's predicted normal value

               -  If change in FEV1 &lt; 4% of patient's predicted normal value, then this requirement
                  must be met after retesting during the run-in period, at least 24 hours prior to
                  Day -1

          -  FEV1/FVC &lt; 70%

        Exclusion Criteria:

          -  Patient has a history of asthma, allergic rhinitis, or atopy

          -  Patient has a blood eosinophil count &gt; 500/microliter

          -  Patient had a COPD exacerbation or a lower respiratory tract infection within 8 weeks
             prior to screening, or during the run-in period, that resulted in the use of an
             antibiotic, or oral or parenteral corticosteroids

          -  Patient is on an inhaled corticosteroid that has been initiated, or the effective dose
             has been changed, within 4 weeks prior to screening or during the run-in period

          -  Patient has an uncontrolled cardiovascular (e.g., uncontrolled hypertension),
             respiratory, hematologic, immunologic, renal, neurologic, hepatic, endocrine (e.g.,
             uncontrolled diabetes mellitus) or other disease, or any condition that might, in the
             judgment of the Investigator, place the patient at undue risk or potentially
             compromise the results or interpretation of the study

          -  Patient has a history of coronary artery disease, cerebrovascular disease, cardiac
             arrhythmias

          -  Patient has a concomitant disease of poor prognosis (e.g., cancer)

          -  Patient has a serum potassium value ≤ 3.5 mEq/L or &gt;5.5mEq/L and/or a fasting serum
             glucose value ≥ 140 mg/dL

          -  Patient has an abnormal QTc Fridericia interval value in the Screening visit ECG test
             (i.e., &gt; 450 msec in males or &gt; 470 msec in females)

          -  Patient has developed Cor Pulmonale

          -  Patient is receiving long term oxygen therapy, i.e., ≥ 16 hours/24-hour period, every
             day

          -  Patient has a known intolerance/hypersensitivity to Beta2-adrenergic agonists,
             propellant gases/excipients

          -  Patient is receiving treatment with a tricyclic antidepressant or a monoamine oxidase
             inhibitor (MAOI)

          -  Patient has received a live-attenuated virus vaccination within two weeks prior to
             screening or during the run-in

          -  Patient is pregnant or lactating female, or female at risk of pregnancy (i.e., not
             using an adequate contraceptive method)

          -  Patient is mentally or legally incapacitated

          -  Patient has participated in another investigational study within 30 days prior to
             screening

          -  Patient abuses alcohol or other substances

          -  Patient is potentially non-compliant or unable to perform required outcome
             measurements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Make, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Medical &amp; Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E Linberg, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chiesi USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clopton Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABM Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD - Clinical Trials Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Healthcare Assessment Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research - DeLand, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hospital and Helath Services, Center for Clinical Trials</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSite, LLC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSite</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley Clinical Research</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Pharmaceutical Research</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Center for Clinical Research</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Consultants - Research Department</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowcountry Lung and Critical Care, PA</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research, Ltd.</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breath of Life Research Institute</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Allergy/Asthma</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordinace pro nemoci dychaciho ustroji</name>
      <address>
        <city>Beroun</city>
        <zip>266 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OTRAN</name>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni a alergologicka ambulance</name>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumolog, internista</name>
      <address>
        <city>Lovosice</city>
        <zip>310 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni ambulance</name>
      <address>
        <city>Praha 3 - Zizkov</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce Plicni ambulance</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni ambulance Rokycany</name>
      <address>
        <city>Rokycany</city>
        <zip>337 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medars GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenzentrum Geesthacht</name>
      <address>
        <city>Geesthacht</city>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut GmbH</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut Niederlassung Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20535</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Koch-Klinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMO, MD GmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IFG GmbH</name>
      <address>
        <city>Ruedersdorf</city>
        <zip>15565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcare Specjalistyczna Opieka Medyczna NZOZ</name>
      <address>
        <city>Gdansk</city>
        <zip>80-433</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Non-nocere</name>
      <address>
        <city>Gdansk</city>
        <zip>80-847</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pulmonologii i Alergologii</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ w Proszowicach Oddzial Chorob Pluc</name>
      <address>
        <city>Proszowice</city>
        <zip>32-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Brasov</name>
      <address>
        <city>Brasov</city>
        <zip>500326</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Urgenta &quot;Prof. Dr. Dimitrie Gerota&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>010457</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta Militar Central &quot;Davila&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic &quot;Sf. Maria&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Pneumoftisiologie &quot;M. Nasta&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Pneumoftiziologie Constanta</name>
      <address>
        <city>Constanta</city>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCT Lung Institute</name>
      <address>
        <city>Mowbray</city>
        <state>Cape Town</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiervlei Trial Center, Karl Bremer Hospital</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000531-10</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <reference>
    <citation>Matera MG, Cazzola M. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? Drugs. 2007;67(4):503-15. Review.</citation>
    <PMID>17352511</PMID>
  </reference>
  <reference>
    <citation>Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. Review.</citation>
    <PMID>16022567</PMID>
  </reference>
  <reference>
    <citation>Matsukawa M, Takeda K, Shima H, Tagawa K, Banno K, Sato T. Enzyme-linked immunosorbent assay for TA-2005-glucuronide in human plasma. J Pharm Biomed Anal. 1998 Jun;17(2):245-54.</citation>
    <PMID>9638577</PMID>
  </reference>
  <reference>
    <citation>Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol. 1998 Jan;53(1):128-34.</citation>
    <PMID>9443940</PMID>
  </reference>
  <reference>
    <citation>Rossoni G, Manfredi B, Razzetti R, Civelli M, Bongrani S, Berti F. Positive interaction of the beta2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guinea-pigs. Br J Pharmacol. 2005 Feb;144(3):422-9.</citation>
    <PMID>15655502</PMID>
  </reference>
  <reference>
    <citation>Rossoni G, Manfredi B, Razzetti R, Civelli M, Berti F. Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther. 2007;20(3):250-7. Epub 2006 Mar 14.</citation>
    <PMID>16533614</PMID>
  </reference>
  <reference>
    <citation>Voss HP, Shukrula S, Wu TS, Donnell D, Bast A. A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther. 1994 Oct;271(1):386-9.</citation>
    <PMID>7965739</PMID>
  </reference>
  <reference>
    <citation>Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting, and selective beta 2-adrenoceptor agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other beta 2-agonists. Biol Pharm Bull. 1994 Aug;17(8):1047-52.</citation>
    <PMID>7820105</PMID>
  </reference>
  <reference>
    <citation>Voss HP, Donnell D, Bast A. Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol. 1992 Dec 1;227(4):403-9.</citation>
    <PMID>1359974</PMID>
  </reference>
  <reference>
    <citation>Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and beta 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol. 1991 Oct;57(2):175-85.</citation>
    <PMID>1687479</PMID>
  </reference>
  <reference>
    <citation>Spadari-Bartfisch RC, Santos IN, Vanderlei LC, Marcondes FK. Pharmacological evidence for beta2-adrenoceptor in right atria from stressed female rats. Can J Physiol Pharmacol. 1999 Jun;77(6):432-40.</citation>
    <PMID>10537229</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <name_title>Steven Linberg/ Managing Director</name_title>
    <organization>Chiesi Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

